Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Change in Accured Expenses (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Change in Accured Expenses for 4 consecutive years, with $443000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 80.34% to $443000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.5 million, a 32.59% increase, with the full-year FY2024 number at $1.6 million, up 319.45% from a year prior.
  • Change in Accured Expenses was $443000.0 for Q3 2025 at Century Therapeutics, down from $707000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.9 million in Q3 2023 to a low of -$6.5 million in Q1 2025.
  • A 4-year average of -$37666.7 and a median of $707000.0 in 2025 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: plummeted 310.87% in 2023, then surged 397.06% in 2025.
  • Century Therapeutics' Change in Accured Expenses stood at $1.1 million in 2022, then tumbled by 310.87% to -$2.4 million in 2023, then soared by 221.74% to $2.9 million in 2024, then tumbled by 84.76% to $443000.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Change in Accured Expenses are $443000.0 (Q3 2025), $707000.0 (Q2 2025), and -$6.5 million (Q1 2025).